Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

EVOPOINT BIOSCIENCES USA, INC.

Home Clinical Trial Sponsors and OrganizationsEVOPOINT BIOSCIENCES USA, INC.

EVOPOINT BIOSCIENCES USA, INC.

300 Baker Ave Ste 300, Concord, Massachusetts, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

2

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

1

50.0%

Phase 3

1

50.0%

Trial Status Distribution

Completed

1

50.0%

Recruiting

1

50.0%

Clinical Trials

Trials sponsored by this organization (2)

A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-XNW4107 in Comparison with Imipenem/Cilastatin/Relebactam in Adults with Hospital Acquired Bacterial Pneumonia or Ventilator Associated Bacterial Pneumonia

Jan 2023450 participants

A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-XNW4107 in Comparison with Imipenem/Cilastatin/Relebactam in Adults with Hospital Acquired Bacterial Pneumonia or Ventilator Associated Bacterial Pneumonia

58 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials2
Approvals
News

Back to Organizations